Navigation Links
Genoptix, Inc. to Announce First Quarter 2009 Financial Results
Date:4/9/2009

CARLSBAD, Calif., April 9 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a provider of personalized diagnostic services, announced today that it expects to report its financial results for the first quarter of 2009 after closing of the NASDAQ Global Market on Thursday, April 30, 2009.

A conference call hosted by President and CEO, Dr. Tina S. Nova, and other members of senior management will take place on the same day at 2:00pm PDT (5:00pm EDT) and will be webcast live on the Genoptix website.

To access the live conference call via phone, dial 866-383-8119 in the U.S. or Canada and 617-597-5344 for international callers. Please specify to the operator that you would like to join the "Genoptix First Quarter 2009 Earnings Conference Call." The participant code for the call is 67492694. If you are unable to listen to the live webcast, a replay of the call will be available through Thursday, May 7, 2009. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 17952469.

The conference call will be webcast live on the Internet and is accessible through the investor relations section of the Genoptix website at www.genoptix.com, or by accessing the external website, www.fulldisclosure.com. To participate in the webcast, please connect to the Genoptix website several minutes prior to the start time to register, download and install any necessary software that may be required. An online replay is planned to follow shortly after and will be available until Thursday, May 28, 2009.

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix' highly trained hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Founded in 1999, Genoptix completed its initial public offering in November 2007 and has been profitable since the first quarter of that year.

Any statements in this press release or that may be made on the Genoptix conference call about expectations, beliefs, plans, objectives, assumptions or future events, or future performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties that Genoptix faces, please refer to the "Risk Factors" section in the Company's most recent Annual Report on Form 10-K, as well as other subsequent filings with the Securities and Exchange Commission. Genoptix assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Genoptix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genoptix, Inc. Announces Pricing for Initial Public Offering
2. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... Bionic Sports Nutrition LLC, an American company devoted to developing high-quality nutritional supplements ... Trade Show in Hilton Head, SC. , Bionic Sports Nutrition manufactures its entire ... to all clients at reasonable prices. At the ECRM trade show, it had a ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, ... everyday lives, recently attended the January ECRM Trade Show in Hilton Head, SC, ... for its large range of supplements that keep the body functioning at its ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Michael and Betsy ... Farber Cancer Institute. For Betsy, the clinical trial has been life-saving as she ... not worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. She ...
(Date:1/20/2017)... York, NY (PRWEB) , ... January 20, 2017 ... ... – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have been ... body with optimal conditions to perform during your workout. , After a successful ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and earnest tale ... each of his children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, ... City, and impassioned writer. , When asked of her new book, Marjorie says, “‘The ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- According to a study conducted by Persistence Market ... a CAGR of 6.5% during the forecast period 2016-2024. According to ... be the leading market for cryotherapy globally during the forecast period  ... Highlights from the ... and adequate supply of gas in order to provide smoother maintenance ...
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... blood analysis instruments and consumables for the medical and ... discuss its financial results for the third quarter fiscal ... be at 4:15 p.m. ET on Thursday, January 26, ... third quarter fiscal year 2017 after the market closes ...
(Date:1/19/2017)... Jan. 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... specializing in the treatment of non-melanoma skin cancers ... superficial radiation therapy, today announced that it will ... financial results on Thursday, February 2, 2017 after the ... a conference call with the investment community on Thursday, ...
Breaking Medicine Technology: